Yuan Zhang

Dr. Yuan Zhang


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2018 in Prenatal Diagnosis
Verified
Journal Article
Closed access
PDF file
YZYuan Zhang
Yuan Zhang
XHXia He
Xia He
XXXuan Xiong
Xuan Xiong
JCJunlan Chuan
Junlan Chuan
LZLei Zhong
Lei Zhong
DYDongke Yu
Dongke Yu

25 August 2025 in BMJ Mental Health
Verified
Journal Article
Open access
PDF file
YZYuan Zhang
Yuan Zhang
YGYiyuan Gao
Yiyuan Gao
YZYazhu Zou
Yazhu Zou
YYYu Ye
Yu Ye
FJFugui Jiang
Fugui Jiang
ZZZhili Zou
Zhili Zou
Question: How effective is pharmacogenomic (PGx)-guided antidepressant treatment compared with treatment-as-usual (TAU) in major depressive disorder (MDD), and how do ethnicity, disease severity and genetic panel scope influence outcomes? Study selection and analysis: This systematic review and meta-analysis comprised 13 randomised controlled trials (2013–2024) comparing PGx-guided therapy with TAU in MDD. PubMed, Ovid Embase, Ovid Medline, Ovid PsycINFO and the Cochrane Library were searched up to December 2024. Outcomes included response and remission rates at 8 and 12 weeks. Subgroup analyses examined ethnicity and MDD severity. Cumulative meta-analyses assessed gene panel size. The pooled risk ratios (RRs) with 95% CIs were calculated to estimate the overall effect. Findings: PGx-guided treatment significantly improved response rates at 8 weeks (RR 1.23, 95% CI 1.05 to 1.43) and 12 weeks (RR 1.29, 95% CI 1.17 to 1.43). Remission was significant at 8 weeks (RR 1.37, 95% CI 1.19 to 1.57) but not at 12 weeks (RR 1.56, 95% CI 0.93 to 2.61). Benefits appeared stronger in the Asian country subgroup compared with non-Asian country subgroup (interaction p=0.02), but this requires validation due to the smaller Asian country sample size. No significant subgroup differences were observed between the MDD not-specified and MDD difficult-to-treat subgroups, despite the latter demonstrating significant improvements in both response and remission rates with PGx-guided treatment compared with TAU at 8 weeks. Cumulative analyses showed effect sizes plateaued, with broader panels offering minimal incremental gains. Conclusions: PGx-guided treatment seems to offer moderate benefits for antidepressant efficacy, with potential advantages in Asian and difficult-to-treat subgroups. Genetic and ethnic variability in drug metabolism underscores the need for population-specific approaches. While multigene panels show clinical benefits plateau, suggesting cost-benefit optimisation is critical. Future research should address adverse events, the cost‐effectiveness of expanded panels, long‐term remission outcomes and treatment efficacy across more precisely stratified disease severity levels to maximise clinical relevance. PROSPERO registration number: CRD42024570014.

23 September 2016 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
JCJunlan Chuan
Junlan Chuan
YZYuan Zhang
Yuan Zhang
XHxia he
xia he
YZYuxuan Zhu
Yuxuan Zhu
LZLei Zhong
Lei Zhong
HXHongtao Xiao
Hongtao Xiao
Telavancin is approved to treat complicated skin and skin structure infections, hospital-acquired and ventilator-associated bacterial pneumonia caused by Staphylococcus aureus. A previous meta-analysis of randomised controlled trials suggested that it might be an alternative to vancomycin in cases of difficult-to-treat meticillin-resistant Staphylococcus aureus infections. We did a meta-analysis including new trials to access the efficacy and safety of telavancin.

19 February 2023 in World Journal of Psychiatry
Verified
Journal Article
Open access
ZZZhi-Li Zou
Zhi-Li Zou
YYYu Ye
Yu Ye
BZBo Zhou
Bo Zhou
YZYuan Zhang
Yuan Zhang
Identification and characterization of noncoding RNAs-associated competing endogenous RNA networks in major depressive disorder

27 August 2020 in PeerJ
Verified
Journal Article
Open access
PDF file
GCGuo Chen
Guo Chen
JZJingwei Zhang
Jingwei Zhang
LZLijuan Zhang
Lijuan Zhang
XXXuan Xiong
Xuan Xiong
DYDongke Yu
Dongke Yu
YZYuan Zhang
Yuan Zhang
Background: Circadian genes have been suggested to play an important role in lung pathology. However, it remains unknown whether polymorphisms of these genes are associated with chronic obstructive pulmonary disease (COPD). Here, we aimed to investigate the association of circadian genes polymorphisms with COPD in a case-control study of 477 COPD patient and 323 control Han Chinese persons. Methods: Genotyping assays were carried out for nine single nucleotide polymorphisms (SNPs) from five circadian genes (PER3, CLOCK, RORB, BMAL1 and CRY2) that were previously identified in lung pathology. Age, sex, BMI and smoking status and comorbidities were recorded for all subjects. Results: No significant association was found in all SNP sites in overall subjects and no significant difference was found in age, sex, smoking status stratification analysis. Discussion: The findings of this investigation indicated the effect of circadian genes polymorphisms on COPD susceptibility may only be small and possibly dependent on the subject factors, such as age and sex.

19 July 2023 in World Journal of Psychiatry
Verified
Journal Article
Open access
ZZZhi-Li Zou
Zhi-Li Zou
JQJian Qiu
Jian Qiu
XZXiao-Bo Zhou
Xiao-Bo Zhou
YHYu-Lan Huang
Yu-Lan Huang
JWJin-Yu Wang
Jin-Yu Wang
YZYuan Zhang
Yuan Zhang
Genetic factors play an important role in the pathogenesis of panic disorder (PD). However, the effect of genetic variants on PD remains controversial. To evaluate the associations between glutamate decarboxylase 1 (GAD1) gene polymorphisms and PD risk and assess the effect of GAD1 gene polymorphisms on the severity of clinical symptoms in PD. We recruited 230 PD patients and 224 healthy controls in this study. All participants were assessed for anxiety and panic symptom severity using the Hamilton Anxiety Rating Scale (HAM-A) and Panic Disorder Severity Scale (PDSS). GAD1 gene polymorphisms (rs1978340 and rs3749034) were genotyped and assessed for allele frequencies. There were no significant differences between cases and controls in the genotype distributions or allele frequencies of GAD1 (rs1978340 and rs3749034). In addition, the effect of GAD1 (rs1978340 and rs3749034) on PD severity was not significant. However, regarding respiratory symptoms, patients with the GAD1 rs1978340 A/A genotype had significantly higher scores than those with the A/G or G/G genotype. Here, we showed that the A/A genotype of GAD1 rs1978340 was associated with increased severity of respiratory symptoms in patients with PD.